Cancer Family
Malignant Genitourinary System Neoplasm
CI-CAN-00000233Explore in graph →
3,546 active trials61 approved drugs295 evidence items
- NCIt
- C156484
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000233Explore in graph →
Clinical trials
15,539 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,963)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04102436 | Non-Viral TCR Gene Therapy | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Mar 12, 2024 | clinicaltrials |
| NCT05689359 | Evaluation of Hydroxychloroquine to Prevent CIPN | withdrawn | Phase 2 | 0 | University of ArizonaOTHER | 0 | Mar 8, 2024 | clinicaltrials |
| NCT05034562 |
| withdrawn |
| Phase 2 |
| 0 |
| M.D. Anderson Cancer CenterOTHER |
| 0 |
| Mar 7, 2024 |
| clinicaltrials |
| NCT06018116 | A Canadian Trial of Bicalutamide in Patients Receiving Maintenance Avelumab for Metastatic Urothelial Cancer.(CANUCK-01) | withdrawn | Phase 2 | 0 | CHU de Quebec-Universite LavalOTHER | 1 | Feb 15, 2024 | clinicaltrials |
| NCT03735589 | Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Nov 22, 2023 | clinicaltrials |
| NCT05998941 | A Trial of TQB2868 Plus Platinum-based Chemotherapy With or Without Bevacizumab in the First-line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer | withdrawn | Phase 2 | 0 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Nov 22, 2023 | clinicaltrials |
| NCT02232646 | A Study of BBI503 in Adult Patients With Advanced Urologic Malignancies | withdrawn | Phase 2 | 0 | Sumitomo Pharma America, Inc.INDUSTRY | 0 | Nov 14, 2023 | clinicaltrials |
| NCT06050954 | A Pilot Study of Circulating Tumor DNA Adaptive Risk Maintenance Approach for Bladder Cancer (CARMA)(CARMA) | withdrawn | Phase 2 | 0 | Fox Chase Cancer CenterOTHER | 0 | Nov 9, 2023 | clinicaltrials |
| NCT05120622 | Trial of Local Cystoscopic Injection of Tremelimumab Plus Systemic Durvalumab for High Risk Non-Muscle Invasive Bladder Cancer(Rideau) | withdrawn | Phase 1 / Phase 2 | 0 | University of British ColumbiaOTHER | 1 | Oct 31, 2023 | clinicaltrials |
| NCT06090318 | Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss | withdrawn | Phase 1 / Phase 2 | 0 | Rain Oncology IncINDUSTRY | 0 | Oct 19, 2023 | clinicaltrials |
| NCT05295589 | Comparing Standard of Care Chemotherapy Treatment to the Combination of Copanlisib and Olaparib for Recurrent Platinum Resistant Ovarian Cancer That Has Progressed Through PARP Inhibitor Therapy | withdrawn | Phase 2 | 0 | National Cancer Institute (NCI)NIH | 1 | Sep 26, 2023 | clinicaltrials |
| NCT05201001 | APX005M in Patients With Recurrent Ovarian Cancer(APX005M) | withdrawn | Phase 2 | 0 | Nordic Society of Gynaecological Oncology - Clinical Trials UnitOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT05176288 | Avelumab, Palbociclib and Axitinib in Advanced RCC(APART) | withdrawn | Phase 2 | 0 | Bradley A. McGregor, MDOTHER | 0 | Sep 7, 2023 | clinicaltrials |
| NCT00489710 | Talabostat in Treating Patients With Metastatic Kidney Cancer | withdrawn | Phase 2 | 0 | University of NebraskaOTHER | 0 | Aug 22, 2023 | clinicaltrials |
| NCT04781374 | Neratinib in Patients With Metastatic Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 11, 2023 | clinicaltrials |
| NCT05614453 | Tislelizumab in Combination With Sitravatinib for Recurrent/Metastatic Cervical Cancer After Platinum-Based Chemotherapy(ITTACC) | withdrawn | Phase 2 | 0 | Australia New Zealand Gynaecological Oncology GroupOTHER | 0 | Jun 29, 2023 | clinicaltrials |
| NCT04995978 | Insulin Resistance and Androgen Deprivation Therapy | withdrawn | Phase 2 | 0 | St. Louis UniversityOTHER | 1 | Jun 23, 2023 | clinicaltrials |
| NCT04510584 | Maintenance Treatment With Bevacizumab and Atezolizumab for Ovarian Cancer | withdrawn | Phase 2 | 0 | University Health Network, TorontoOTHER | 1 | Jun 6, 2023 | clinicaltrials |
| NCT00771017 | Androgen Ablation Therapy With or Without Vaccine Therapy in Treating Patients With Prostate Cancer | withdrawn | Phase 2 | 0 | Eastern Cooperative Oncology GroupNETWORK | 0 | May 25, 2023 | clinicaltrials |
| NCT04483414 | 68Ga PSMA-11 PET/CT in Recurrent Prostate Cancer | withdrawn | Phase 2 | 0 | Dana MathewsOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT04603365 | Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 0 | May 17, 2023 | clinicaltrials |
| NCT05736952 | Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer | withdrawn | Phase 2 | 0 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | May 11, 2023 | clinicaltrials |
| NCT05107427 | Study of MRx0518 and Avelumab in Patients With Urothelial Carcinoma(AVENU) | withdrawn | Phase 2 | 0 | 4D pharma plcINDUSTRY | 1 | Apr 18, 2023 | clinicaltrials |
| NCT05496192 | A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer | withdrawn | Phase 2 | 0 | Bristol-Myers SquibbINDUSTRY | 2 | Apr 14, 2023 | clinicaltrials |
| NCT05419817 | Pembrolizumab With Sitravatinib in Recurrent Endometrial Cancer and Other Solid Tumors With Deficient Mismatch Repair System | withdrawn | Phase 2 | 0 | Haider MahdiOTHER | 0 | Feb 27, 2023 | clinicaltrials |
| NCT05705700 | Biomarker Study of in Men With PSA Progression on Abi for CR or CS PC (Bio-STAMP) | withdrawn | Phase 2 | 0 | Masonic Cancer Center, University of MinnesotaOTHER | 0 | Feb 27, 2023 | clinicaltrials |
| NCT03982173 | Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors(MATILDA) | withdrawn | Phase 2 | 0 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 0 | Jan 26, 2023 | clinicaltrials |
| NCT04294836 | Curcumin in Advanced Cervical Cancer | withdrawn | Phase 2 | 0 | Instituto Nacional de Cancerologia, ColumbiaOTHER_GOV | 0 | Dec 7, 2022 | clinicaltrials |
| NCT03709550 | Enzalutamide and Decitabine in Treating Patients With Metastatic Castration Resistant Prostate Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | Oct 5, 2022 | clinicaltrials |
| NCT05191017 | Study of NUV-422 in Combination With Enzalutamide in Patients With mCRPC | withdrawn | Phase 1 / Phase 2 | 0 | Nuvation Bio Inc.INDUSTRY | 1 | Aug 5, 2022 | clinicaltrials |
| NCT05263609 | Optimizing Pembrolizumab Therapy With Timing and Intensification With Axitinib | withdrawn | Phase 2 | 0 | University of OklahomaOTHER | 0 | Aug 2, 2022 | clinicaltrials |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women | withdrawn | Phase 2 | 0 | AIDS Malignancy ConsortiumNETWORK | 2 | Jun 21, 2022 | clinicaltrials |
| NCT05104905 | A Phase I/II Open Label Single Centre Trial to Assess the Safety, Tolerability and Efficacy of Single Dose Neoadjuvant Anti-CLEVER-1 Antibody Bexmarilimab in Localised Renal Cell and Colon Carcinoma(RENACOL) | withdrawn | Phase 1 / Phase 2 | 0 | Faron Pharmaceuticals LtdINDUSTRY | 1 | May 11, 2022 | clinicaltrials |
| NCT04331717 | Bariatric Arterial Embolization for Men Starting Hormones for Prostate Cancer(BASH-PC) | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 2, 2022 | clinicaltrials |
| NCT04795596 | Secondary Cytoreductive Surgery in Platinum-resistant Recurrent Ovarian Cancers | withdrawn | Phase 2 / Phase 3 | 0 | Menoufia UniversityOTHER | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Silverback TherapeuticsINDUSTRY | 0 | Apr 12, 2022 | clinicaltrials |
| NCT03035630 | Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma | withdrawn | Phase 2 | 0 | Guru SonpavdeOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT03800784 | Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer | withdrawn | Phase 2 / Phase 3 | 0 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Dec 15, 2021 | clinicaltrials |
| NCT03634150 | Safety and Efficacy of IV Nerofe™ Followed by Doxorubicin, In Metastatic Ovarian Cancer and Triple Negative Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Immune System Key LtdINDUSTRY | 1 | Oct 26, 2021 | clinicaltrials |
| NCT04020094 | Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer(AtezoVax) | withdrawn | Phase 2 | 0 | University of UtahOTHER | 1 | Sep 22, 2021 | clinicaltrials |
| NCT03933761 | Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy(PRECISE) | withdrawn | Phase 2 | 0 | Australia New Zealand Gynaecological Oncology GroupOTHER | 0 | Aug 10, 2021 | clinicaltrials |
| NCT02127151 | A Parp Inhibitor (BMN 673) for Inoperable Advanced eNDometrial cAncer(PANDA) | withdrawn | Phase 2 | 0 | University College, LondonOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT04464967 | Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers | withdrawn | Phase 1 / Phase 2 | 0 | NKGen Biotech, Inc.INDUSTRY | 0 | May 12, 2021 | clinicaltrials |
| NCT01802307 | Focal Therapy for Prostate Cancer | withdrawn | Phase 2 | 0 | University of Maryland, BaltimoreOTHER | 1 | May 11, 2021 | clinicaltrials |
| NCT02497638 | LIpitor and biGuanide to Androgen Delay Trial(LIGAND) | withdrawn | Phase 2 | 0 | University Health Network, TorontoOTHER | 1 | Apr 19, 2021 | clinicaltrials |
| NCT04585932 | Androgen Deprivation Therapy and Apalutamide With or Without Radiation Therapy for the Treatment of Biochemically Recurrent Prostate Cancer, RESTART Study | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 20, 2021 | clinicaltrials |
| NCT01097239 | Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Imperial College LondonOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT04262375 | A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION(DOMINATION) | withdrawn | Phase 2 | 0 | University Health Network, TorontoOTHER | 1 | Nov 17, 2020 | clinicaltrials |
| NCT04197219 | Pembrolizumab With Axitinib in Recurrent Endometrial Cancer | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Nov 5, 2020 | clinicaltrials |
Data updated 22 days agoSource updated Mar 12, 2024source: clinicaltrials